Who
Punit Dhillon
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Skye Bioscience; Director, Arch Therapeutics; President, Oncosec Medical; VP, Finance & Operations, Inovio Pharmaceuticals.
In numbers
- Trades disclosed
- 146
- Buys
- 11
- Sells
- 24
- Bought
- $100.0B
- Sold
- $1.0M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 1 Feb 2008
- Last trade
- 7 Aug 2026
- Last filed
- 7 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 7 Aug 2026 | SKYE Skye BioscienceBiotechnology | SEC FORM 4 Code A | —1,090,000 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | SKYE Skye BioscienceBiotechnology | SEC FORM 4 Code A | —1,090,000 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —125,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,013 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —9,013 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,586 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —21,586 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —250,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —250,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —36,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,360 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —12,360 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —650,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —650,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —125,000 | filing |
News
No headline names them, or the companies they trade most, lately.